Prosecution Insights
Last updated: November 04, 2026
Application No. 18/696,044

PHENYLCOUMARINS FOR TREATING INFLAMMATION

Non-Final OA §102§112
Filed
Mar 27, 2024
Priority
Sep 29, 2021 — provisional 63/249,879 +2 more
Examiner
SHIAO, YIH-HORNG
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Isabel Rivero Cruz
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
709 granted / 976 resolved
+12.6% vs TC avg
Strong +76% interview lift
Without
With
+75.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
46 currently pending
Career history
1014
Total Applications
across all art units

Statute-Specific Performance

§101
6.2%
-33.8% vs TC avg
§103
33.7%
-6.3% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
28.7%
-11.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 976 resolved cases

Office Action

§102 §112
DETAILED ACTION The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Preliminary amendment filed on 03/27/2024 has been entered. Claims 3, 7, 9, 12-15, 18, 19, 21, 23-29, 31, 34, 35, 37, 39-45, and 47 are cancelled. Claims 1, 2, 4-6, 8, 10, 11, 16, 17, 20, 22, 30, 32, 33, 36, 38, 46, and 48 are pending in this application. Claims 17, 20, 22, 30, 32, 33, 36, 38, 46, and 48 are withdrawn. Claims 1, 2, 4-6, 8, 10, 11, and 16 are currently under examination. Priority This application is a 371 of PCT/US2022/045242 filed on 09/29/2022 and claims benefit of US PRO 63/254,266 filed on 10/11/2021 and US PRO 63/249,879 filed on 09/29/2021. Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 63/249,879 or 63/254,266, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. The prior-filed Application No. 63/249,879 disclosed, for example, PNG media_image1.png 200 400 media_image1.png Greyscale , not the compounds required by claims 1, 2, 4-6, 8, 10, 11, and 16. The prior-filed Application No. 63/254,266 disclosed only the compounds: PNG media_image2.png 200 400 media_image2.png Greyscale and PNG media_image3.png 200 400 media_image3.png Greyscale , not the broader recitations including “Formula I: PNG media_image4.png 200 400 media_image4.png Greyscale … R2, R3, and R4 are each independently selected from… halo, cyano, azido, C1-C6alkyl, C1-C6haloalkyl, RxO-, and RxRYN-… Rx and RY are independently selected at each occurrence from hydrogen, C1-C6alkyl…optionally substituted with one or more Y groups as allowed by valency; and Y is independently selected at each occurrence from alkyl, haloalkyl… sulfone, sulfoxide, sulfonylamino, or thiol”. Thus, the priority date of claims 1, 2, 4-6, 8, 10, 11, and 16 is 09/29/2022. Election/Restrictions Applicant's election without traverse of Group I invention (claims 1, 2, 4-6, 8, 10, 11, and 16) and species ( PNG media_image5.png 200 400 media_image5.png Greyscale ) in the reply filed on 10/01/2026 is acknowledged. Claims 17, 20, 22, 30, 32, 33, 36, 38, 46, and 48 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention or species, there being no allowable generic or linking claim. Thus, claims 1, 2, 4-6, 8, 10, 11, and 16 are currently under examination. Information Disclosure Statement The information disclosure statement (IDS) filed on 03/27/2024 has been considered. Specification/Claim Objections Specification: The disclosure is objected to because of the following informalities: The nomenclature “5-O-[ß-D-apiofuranosyl-(1→6)-ß-D-glucopyranosyl]-7-methoxy-3',4'-dihydroxy-4-phenylcoumarin” (p. 44-47) refers to the chemical structure of “ PNG media_image6.png 200 400 media_image6.png Greyscale ” (see Mata et al. Pharmaceutical Biology 2008, Vol. 46, Nos. 1–2, pp. 105–110), not the disclosed “ PNG media_image7.png 200 400 media_image7.png Greyscale ”. Appropriate correction is required. Claims 1, 2, 4, 6, and 8 are objected to because of the following informalities: In claim 1, change the incorrect conjunction “and” immediately before the recitation “RxRYN-“ (line 7) to “or” because the preceding “selected from” should be followed by conjunction “or”; and replace the incorrect recitation “may be” (line 11), which means possibly, to “is”. In claims 2, 4, 6, and 8, change the incorrect conjunction “and” (line 2 of claims 2, 4, 6, and 8) to “or” because the preceding “selected from” should be followed by conjunction “or”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 2, 4-6, 8, 10, 11, and 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 2, 4-6, 8, 10, and 11 depend from claim 1. Claims 1 and 16 recite “derivative”, which is not defined in the Specification and thus the scope of the recitation is unclear. Applicant is advised to insert the word “structural” immediately before the recitation “derivative”. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, 4-6, 8, 10, 11, and 16 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Woodard (Dissertation, Graduate Program in Pharmaceutical Sciences, The Ohio State University, 2019, hereinafter referred to as Woodard ‘2019, also listed in IDS filed on 03/27/2024). With regard to structural limitations “a compound of Formula I: PNG media_image4.png 200 400 media_image4.png Greyscale wherein: R1 is PNG media_image8.png 138 355 media_image8.png Greyscale (or the compound is elected PNG media_image5.png 200 400 media_image5.png Greyscale ; or wherein R2 is methoxy, R3 is isopropoxy, and R4 is hydroxy)” (claims 1, 2, 4-6, 8, 10, 11), and “a pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient” (claim 16): Woodard ‘2019 disclosed derivatization of 24 to form a new compound, 40 [OiPr = isopropoxy or OCH(CH3)2]: PNG media_image9.png 200 400 media_image9.png Greyscale . MS spectrum of 40 (636.21 Da, C30H36O15): PNG media_image10.png 200 400 media_image10.png Greyscale (page 151/360, Figure 44; page 163/360, Figure 55). The three 4-phenylcoumarin glycoside natural products from the diverse library (22, 23, and 24) and the isopropyl ether derivative (40), was evaluated for PPAR-y activity at 50 μg/mL in HeLa cells (page 164/360, para. 3). Thus, these teachings of Woodard ‘2019 anticipate Applicant’s claims 1, 2, 4-6, 8, 10, 11, and 16. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YIH-HORNG SHIAO whose telephone number is (571)272-7135. The examiner can normally be reached Mon-Thur, 08:30 am to 07:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YIH-HORNG SHIAO/Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Mar 27, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781216
IMPROVED REMOVAL OF RNA AND CONTAMINANTS FROM DNA PLASMID PREPARATIONS BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY
3y 7m to grant Granted Nov 03, 2026
Patent 12779086
WOUND DRESSING COMPRISING HYALURONIC ACID-CALCIUM AND POLYLYSINE AND MANUFACTURING METHOD THEREFOR
2y 12m to grant Granted Nov 03, 2026
Patent 12778971
COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS
2y 11m to grant Granted Nov 03, 2026
Patent 12751470
Use Of Ionic Polymers In Biomass Processing For Preparation Of Animal Feed Additive
4y 2m to grant Granted Oct 06, 2026
Patent 12751909
COSMETIC PREPARATION
3y 2m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
99%
With Interview (+75.9%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 976 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month